92 related articles for article (PubMed ID: 15629263)
1. Effects of salmeterol on cilia and mucus in COPD and pneumonia patients.
Piatti G; Ambrosetti U; Santus P; Allegra L
Pharmacol Res; 2005 Feb; 51(2):165-8. PubMed ID: 15629263
[TBL] [Abstract][Full Text] [Related]
2. Ciliary beating is depressed in nasal cilia from chronic obstructive pulmonary disease subjects.
Yaghi A; Zaman A; Cox G; Dolovich MB
Respir Med; 2012 Aug; 106(8):1139-47. PubMed ID: 22608352
[TBL] [Abstract][Full Text] [Related]
3. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro.
Devalia JL; Sapsford RJ; Rusznak C; Toumbis MJ; Davies RJ
Pulm Pharmacol; 1992 Dec; 5(4):257-63. PubMed ID: 1362105
[TBL] [Abstract][Full Text] [Related]
4. Nasal ciliary function and ultrastructure in Down syndrome.
Piatti G; Allegra L; Ambrosetti U; De Santi MM
Laryngoscope; 2001 Jul; 111(7):1227-30. PubMed ID: 11568545
[TBL] [Abstract][Full Text] [Related]
5. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
6. Salmeterol improves fluid clearance from alveolar-capillary membrane in COPD patients: a pilot study.
Di Marco F; Guazzi M; Sferrazza Papa GF; Vicenzi M; Santus P; Busatto P; Piffer F; Blasi F; Centanni S
Pulm Pharmacol Ther; 2012 Feb; 25(1):119-23. PubMed ID: 22245487
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
8. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
9. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
[TBL] [Abstract][Full Text] [Related]
10. Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype.
Koblizek V; Tomsova M; Cermakova E; Papousek P; Pracharova S; Mandalia RA; Ceral J; Novosad J; Fila L; Sedlak V; Ruta J; Bartos V; Salajka F; Hrnciarik M
Rhinology; 2011 Oct; 49(4):397-406. PubMed ID: 21991564
[TBL] [Abstract][Full Text] [Related]
11. The effect of some preservatives used in nasal preparations on the mucus and ciliary components of mucociliary clearance.
Batts AH; Marriott C; Martin GP; Wood CF; Bond SW
J Pharm Pharmacol; 1990 Mar; 42(3):145-51. PubMed ID: 1974607
[TBL] [Abstract][Full Text] [Related]
12. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
13. Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers.
Duchateau GS; Graamans K; Zuidema J; Merkus FW
Laryngoscope; 1985 Jul; 95(7 Pt 1):854-9. PubMed ID: 4010429
[TBL] [Abstract][Full Text] [Related]
14. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
[TBL] [Abstract][Full Text] [Related]
15. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
[TBL] [Abstract][Full Text] [Related]
16. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
17. [Examination of function and structure of respiratory cilia of adult patients suffering from chronic obstructive pulmonary disease (COPD)--comparison of nasal and bronchial mucosa (pilot of CILIARY STUDY)].
Koblízek V; Dobesová T; Salajka F; Cermáková E; Tomsová M; Pohnetalová D; Papousek P; Bartos V; Paráková Z; Ruta J; Sedlák V
Vnitr Lek; 2009 Nov; 55(11):1035-42. PubMed ID: 20017434
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
19. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
[No Abstract] [Full Text] [Related]
20. Endurance shuttle walking test: responsiveness to salmeterol in COPD.
Brouillard C; Pepin V; Milot J; Lacasse Y; Maltais F
Eur Respir J; 2008 Mar; 31(3):579-84. PubMed ID: 18057052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
